AtaiBeckley Inc. (ATAI)

In October 2025, Atai Life Sciences and Beckley Psytech received U.S. FDA Breakthrough Therapy Designation for BPL-003 for treatment-resistant depression and priced a public offering of common shares to raise approximately $130 million. In November 2025, Atai Life Sciences N.V. completed a strategic combination with Beckley Psytech Limited, creating AtaiBeckley, and redomiciled to the United States. In December 2025, AtaiBeckley Inc. was added to the NASDAQ Biotechnology Index (NBI). In February 2026, AtaiBeckley announced positive topline results from an exploratory Phase 2a trial of EMP-01 in social anxiety disorder. In March 2026, the company reported a successful End-of-Phase 2 meeting with the FDA for BPL-003 and reported its Q4 and full-year 2025 results, with cash and short-term securities totaling $220.7 million. AtaiBeckley was also added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S. benchmark indices.

As a clinical-stage biopharmaceutical company, AtaiBeckley's products are still in development, and traditional demand seasonality does not directly apply. The demand for the types of treatments AtaiBeckley is developing is driven by broader trends, including the rising global prevalence of mental health disorders and the increasing acceptance of psychedelic-assisted therapy. Stock seasonality analysis suggests that July has historically offered the highest probability of positive returns for ATAI stock, while March may not be an ideal month for investment.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, operating within the biotechnology sector, specifically in the pharmaceutical and psychedelic medicine industry. The company aims to revolutionize the mental health treatment landscape by developing psychedelic and non-psychedelic compounds for conditions often resistant to conventional therapies. Its major product candidates include BPL-003 (mebufotenin benzoate nasal spray) in Phase 2a and 2b clinical studies for treatment-resistant depression (TRD) and alcohol use disorder, VLS-01 (DMT buccal film) in Phase 2 clinical development for TRD, EMP-01 ((R)-MDMA HCl) in Phase 2 clinical development for social anxiety disorder, and RL-007 (inidascamine) in a Phase 2b trial for cognitive impairment associated with schizophrenia. Other pharmaceutical candidates include ibogaine (IBX-210, DMX-1002), EGX-121, 5-MeO-DMT, psilocin (ELE-101), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101).

AtaiBeckley was founded in 2018 and was originally headquartered in Berlin, Germany. Following a strategic combination with Beckley Psytech Limited and redomiciliation in December 2025, the company's headquarters are now in New York, NY, United States. The company conducts global clinical trials and has research and development operations across North America and Europe.

AtaiBeckley generally holds a positive brand reputation, particularly within the investment community focused on biotechnology and mental health innovation. The company has received a consensus rating of "Buy" or "Strong Buy" from analysts, with an average rating score of 3.00. Positive clinical trial results for its drug candidates and the FDA's Breakthrough Therapy Designation for BPL-003 have contributed to a favorable perception. In January 2023, a leading drug candidate (arketamine, PCN-101) failed to meet its primary endpoint, leading to staff layoffs, which was a historical event impacting the company.

The ownership structure of AtaiBeckley Inc. is comprised of institutional, insider, and retail investors. Approximately 1.10% to 3.48% of the company's stock is held by institutional investors, 23.34% by insiders, and a significant portion, around 73.18%, by public companies and individual investors. Major institutional holders include Apeiron Investment Group Ltd., Adage Capital Management, L.P., ARK Investment Management LLC, Morgan Stanley Investment Management Inc., BlackRock, Inc., Deep Track Capital, LP, Foresite Capital Management, LLC, Marshall Wace LLP, RTW Investments, LP, and T. Rowe Price Investment Management, Inc. Key insiders who own company stock include Apeiron Investment Group Ltd., Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar, and Srinivas Rao.